LIVN LivaNova Plc

LivaNova PLC Announces Chief Financial Officer Resignation

LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced its Chief Financial Officer, Vivid Sehgal, is leaving the company to pursue other opportunities. The company has an external search underway to identify a replacement. Sehgal will continue as CFO and will support an orderly transition to his successor.

“Vivid has been the company’s CFO since its inception in October 2015 and has been an integral part of our Executive Leadership team,” said Damien McDonald, LivaNova’s Chief Executive Officer. “His leadership, insights and guidance have been instrumental in building a strong team, while establishing financial disciplines across the portfolio. His presence, knowledge and leadership will be important through the transition period. We wish to thank him for his many contributions in helping to position the company for sustainable growth.”

“I have a number of things I wish to do, not the least of which will be spending more time with family and pursuing personal interests,” said Vivid Sehgal, LivaNova’s CFO. “I am very proud of what we have accomplished for our employees and shareowners in a short time as a new public company. We made progress in critical areas, including achieving merger-related synergies, restructuring, capital formation, cost controls and building a sustainable tax strategy. I remain fully committed to helping Damien and the LivaNova team with this important transition.”

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

For more information, please visit www.LivaNova.com.

EN
31/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LivaNova Plc

 PRESS RELEASE

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 202...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $1.02 and adjusted diluted earnings per share of $0.81 Full-year 2024 revenue of $1.25 billion increased 8.7% on a reported bas...

 PRESS RELEASE

LivaNova to Present at the Barclays Global Healthcare Conference

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on th...

 PRESS RELEASE

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial (if dialing from within the U.S.) or (if dial...

 PRESS RELEASE

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. “Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management,” Makatsaria said. “I look forward to collaborating with Natalia to further strengt...

 PRESS RELEASE

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS The...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the . The researchers evaluated the safety and efficacy of LivaNova’s VNS Therapy™ System and its effectiveness on quality of life and daily function in this population of patients with treatment-resistant unipolar depression. Overall, the articles concluded that active VNS Therapy, as compared with a no-stimulation control (or sham VNS Therapy), safely and effective...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch